AU2010277490B2 - Method of producing a polypeptide or virus of interest in a continuous cell culture - Google Patents

Method of producing a polypeptide or virus of interest in a continuous cell culture Download PDF

Info

Publication number
AU2010277490B2
AU2010277490B2 AU2010277490A AU2010277490A AU2010277490B2 AU 2010277490 B2 AU2010277490 B2 AU 2010277490B2 AU 2010277490 A AU2010277490 A AU 2010277490A AU 2010277490 A AU2010277490 A AU 2010277490A AU 2010277490 B2 AU2010277490 B2 AU 2010277490B2
Authority
AU
Australia
Prior art keywords
cell
cells
culture
less
culture system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010277490A
Other languages
English (en)
Other versions
AU2010277490A1 (en
Inventor
Daniel Fleischanderl
Leopold Grillberger
Manfred Reiter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2010277490A1 publication Critical patent/AU2010277490A1/en
Application granted granted Critical
Publication of AU2010277490B2 publication Critical patent/AU2010277490B2/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATED reassignment Baxalta GmbH Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12MAPPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M3/00Tissue, human, animal or plant cell, or virus culture apparatus
    • C12M3/006Cell injection or fusion devices
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0056Xeno-free medium
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489Metalloendopeptidases (3.4.24)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/98Xeno-free medium and culture conditions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/00051Methods of production or purification of viral material
    • C12N2710/00052Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24087ADAMTS13 endopeptidase (3.4.24.87)
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/52Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Sustainable Development (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2010277490A 2009-07-31 2010-08-02 Method of producing a polypeptide or virus of interest in a continuous cell culture Active AU2010277490B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23031309P 2009-07-31 2009-07-31
US61/230,313 2009-07-31
PCT/EP2010/061191 WO2011012725A1 (en) 2009-07-31 2010-08-02 Method of producing a polypeptide or virus of interest in a continuous cell culture

Publications (2)

Publication Number Publication Date
AU2010277490A1 AU2010277490A1 (en) 2012-02-09
AU2010277490B2 true AU2010277490B2 (en) 2014-08-28

Family

ID=42668436

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010277490A Active AU2010277490B2 (en) 2009-07-31 2010-08-02 Method of producing a polypeptide or virus of interest in a continuous cell culture

Country Status (22)

Country Link
US (4) US8580554B2 (https=)
EP (2) EP2459697B1 (https=)
JP (2) JP5808742B2 (https=)
KR (2) KR101885046B1 (https=)
CN (1) CN102549142B (https=)
AU (1) AU2010277490B2 (https=)
BR (1) BR112012002137B8 (https=)
CA (1) CA2769354A1 (https=)
CO (1) CO6491119A2 (https=)
DK (1) DK2459697T3 (https=)
EA (1) EA022219B1 (https=)
ES (1) ES2705206T3 (https=)
HR (1) HRP20182165T1 (https=)
IN (1) IN2012DN00899A (https=)
MX (2) MX2012001274A (https=)
NZ (1) NZ597742A (https=)
PL (1) PL2459697T3 (https=)
PT (1) PT2459697T (https=)
SG (1) SG178176A1 (https=)
SI (1) SI2459697T1 (https=)
TR (1) TR201900213T4 (https=)
WO (1) WO2011012725A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
EP4036207B1 (en) * 2011-01-17 2025-10-22 F. Hoffmann-La Roche AG Use of a separation apparatus in a seed train
ES2970057T3 (es) 2011-05-13 2024-05-24 Octapharma Ag Un procedimiento para aumentar la productividad de células eucarióticas en la producción de FVIII recombinante
PT2837680T (pt) 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
CN203129697U (zh) 2013-02-05 2013-08-14 客贝利(厦门)休闲用品有限公司 一种帐篷架杆
US20140315294A1 (en) 2011-11-24 2014-10-23 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
US9574167B2 (en) 2013-02-15 2017-02-21 Pharyx, Inc. Methods and apparatus for independent control of product and reactant concentrations
AU2014226126B2 (en) 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
ES2842350T3 (es) 2013-03-19 2021-07-13 Cmc Biologics As Un procedimiento para la producción de un producto (por ejemplo, polipéptido) en un proceso de fermentación de cultivo celular continuo
JP6851827B2 (ja) * 2013-08-30 2021-03-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細胞培養中でのウイルスの大規模製造
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
JP2017509659A (ja) 2014-04-01 2017-04-06 アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ 低糖−低グリシンの安定な第viii因子製剤
US9855319B2 (en) 2014-04-01 2018-01-02 Advantech Bioscience Farmacêutica Ltda Stabilization of factor VIII without calcium as an excipient
CN106414719B (zh) * 2014-06-13 2020-02-14 杰特有限公司 生物反应器中重组von Willebrand因子的改进生产
KR20240173213A (ko) 2016-01-26 2024-12-10 베링거 인겔하임 인터내셔날 게엠베하 연결된 관류 대 연속-유동식 교반-탱크 반응기 세포 배양 시스템
WO2017180814A1 (en) 2016-04-15 2017-10-19 Boehringer Ingelheim International Gmbh Cell retention device and method
US20200063086A1 (en) * 2016-12-21 2020-02-27 Hoffmann-La Roche Inc. Growth control of eukaryotic cells
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
WO2019239780A1 (ja) * 2018-06-15 2019-12-19 富士フイルム株式会社 細胞培養方法、細胞培養装置、及び生産物の製造方法
AU2019332764B2 (en) 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
CN113355297A (zh) * 2021-06-23 2021-09-07 吉林冠界生物技术有限公司 一种灌流式培养全悬浮mdck细胞生产重组禽流感病毒的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019512A (en) 1989-03-17 1991-05-28 Baxter International Inc. Spin filter for removing substantially cell-free culture medium from suspension cell culture system
US5626734A (en) 1995-08-18 1997-05-06 University Technologies International, Inc. Filter for perfusion cultures of animal cells and the like
BR0114373A (pt) 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
CA2466881A1 (en) * 2001-11-28 2003-06-05 Sandoz Gmbh Cell culture process
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
ATE544866T1 (de) 2005-06-17 2012-02-15 Baxter Int Adamts13-haltige zusammensetzungen mit thrombolytischer wirkung
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
SG187397A1 (en) * 2007-12-27 2013-02-28 Baxter Int Cell culture processes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBINSON, D.K. et al. Journal of Biotechnology, 1992, Vol.22, pages 41-50. *

Also Published As

Publication number Publication date
US20110086411A1 (en) 2011-04-14
BR112012002137A2 (pt) 2015-09-15
IN2012DN00899A (https=) 2015-04-03
PL2459697T3 (pl) 2019-04-30
SG178176A1 (en) 2012-03-29
US20180051261A1 (en) 2018-02-22
KR20170077286A (ko) 2017-07-05
CN102549142B (zh) 2014-07-16
WO2011012725A8 (en) 2011-05-05
MX353610B (es) 2018-01-18
BR112012002137B1 (pt) 2020-04-14
WO2011012725A1 (en) 2011-02-03
PT2459697T (pt) 2019-01-21
KR101752789B1 (ko) 2017-06-30
EA022219B1 (ru) 2015-11-30
JP2013500710A (ja) 2013-01-10
EA201270213A1 (ru) 2012-06-29
NZ597742A (en) 2014-02-28
US10745672B2 (en) 2020-08-18
EP3480292A1 (en) 2019-05-08
US20190153400A1 (en) 2019-05-23
KR20120038531A (ko) 2012-04-23
KR101885046B1 (ko) 2018-08-02
DK2459697T3 (en) 2019-01-28
US20140038264A1 (en) 2014-02-06
CA2769354A1 (en) 2011-02-03
ES2705206T3 (es) 2019-03-22
HRP20182165T1 (hr) 2019-03-08
JP2015062436A (ja) 2015-04-09
EP2459697A1 (en) 2012-06-06
MX2012001274A (es) 2012-06-01
JP6177260B2 (ja) 2017-08-09
US8580554B2 (en) 2013-11-12
AU2010277490A1 (en) 2012-02-09
TR201900213T4 (tr) 2019-02-21
CO6491119A2 (es) 2012-07-31
JP5808742B2 (ja) 2015-11-10
CN102549142A (zh) 2012-07-04
BR112012002137B8 (pt) 2020-05-12
SI2459697T1 (sl) 2019-03-29
US10221400B2 (en) 2019-03-05
EP2459697B1 (en) 2018-10-17
US9650612B2 (en) 2017-05-16

Similar Documents

Publication Publication Date Title
AU2010277490B2 (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
PT2634242T (pt) Processo melhorado para cultura de células
JP5096920B2 (ja) ウイルス物質の製造方法
HK40008436A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
JP2859679B2 (ja) 新規細胞株
HK1169439A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
HK1169439B (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
EP2307538B1 (en) Scalable process for culturing per.c6 cells and producing products therefrom
Feder 32 Development of large-scale mammalian cell perfusion culture systems
JPH05207874A (ja) 無血清培地
JP2011004754A (ja) 組換え安定細胞クローン、その産生およびその使用
JP6097725B2 (ja) 組換え安定細胞クローン、その産生およびその使用
JP2010099093A (ja) 組換え安定細胞クローン、その産生およびその使用
JP2016178932A (ja) 組換え安定細胞クローン、その産生およびその使用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BAXALTA GMBH; BAXALTA INCORPORATED

Free format text: FORMER OWNER WAS: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.

PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXALTA GMBH; BAXALTA INCORPORATED